Compare Stocks → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ICCMNYSE:NSPRNASDAQ:NVNONASDAQ:SEPA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCMIceCure Medical$1.18-1.7%$1.25$0.52▼$1.57$53.83M0.73621,546 shs25,541 shsNSPRInspireMD$1.91-1.0%$2.35$1.04▼$3.85$44.69M0.8433,075 shs1,019 shsNVNOenVVeno Medical$5.20-0.4%$5.55$2.51▼$6.97$69.26M1.17114,256 shs7,609 shsSEPASEP Acquisition$10.45-14.1%$11.13$8.20▼$17.00$60.71M0.082,856 shs1,714 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCMIceCure Medical0.00%-1.64%0.00%-18.92%-5.46%NSPRInspireMD-3.50%+1.05%-18.56%-34.46%+85.59%NVNOenVVeno Medical+0.77%+6.31%-4.04%+15.23%+28.73%SEPASEP Acquisition+21.60%+19.69%-0.08%+14.07%+22.83%The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICCMIceCure Medical2.657 of 5 stars3.55.00.00.02.80.00.6NSPRInspireMD2.0995 of 5 stars3.50.00.00.01.82.50.6NVNOenVVeno Medical0.1836 of 5 stars0.01.00.00.02.61.70.6SEPASEP AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICCMIceCure Medical3.00Buy$2.95150.00% UpsideNSPRInspireMD3.00Buy$4.85153.93% UpsideNVNOenVVeno MedicalN/AN/AN/AN/ASEPASEP AcquisitionN/AN/AN/AN/ACurrent Analyst RatingsLatest ICCM, SEPA, NVNO, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.004/4/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.003/20/2024ICCMIceCure MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.90 ➝ $2.903/20/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.003/5/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00(Data available from 4/30/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICCMIceCure Medical$3.23M16.67N/AN/A$0.27 per share4.37NSPRInspireMD$6.20M7.21N/AN/A$1.83 per share1.04NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/ASEPASEP AcquisitionN/AN/AN/AN/A($0.63) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICCMIceCure Medical-$14.65M-$0.33N/AN/AN/A-453.76%-86.96%-68.63%5/27/2024 (Estimated)NSPRInspireMD-$19.92M-$1.08N/AN/AN/A-320.97%-55.71%-46.53%5/20/2024 (Estimated)NVNOenVVeno Medical-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%5/6/2024 (Estimated)SEPASEP Acquisition-$2.36MN/A0.00∞N/AN/AN/A-16.47%N/ALatest ICCM, SEPA, NVNO, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/3/2024Q4 2023ICCMIceCure Medical-$0.08-$0.07+$0.01-$0.07N/A$1.26 million 3/6/202412/31/2023NSPRInspireMD-$0.20-$0.16+$0.04-$0.16$1.65 million$1.76 million 2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICCMIceCure MedicalN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ASEPASEP AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICCMIceCure Medical0.033.663.08NSPRInspireMDN/A7.346.99NVNOenVVeno MedicalN/A34.2234.23SEPASEP AcquisitionN/A0.020.02OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICCMIceCure Medical0.62%NSPRInspireMD44.78%NVNOenVVeno Medical34.71%SEPASEP Acquisition3.66%Insider OwnershipCompanyInsider OwnershipICCMIceCure Medical2.44%NSPRInspireMD29.72%NVNOenVVeno Medical17.00%SEPASEP Acquisition20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableICCMIceCure Medical7145.62 million44.51 millionNot OptionableNSPRInspireMD6523.40 million16.45 millionOptionableNVNOenVVeno Medical1913.32 million11.05 millionOptionableSEPASEP AcquisitionN/A5.81 million4.65 millionNot OptionableICCM, SEPA, NVNO, and NSPR HeadlinesSourceHeadlineSEP Acquisition Corp. (NASDAQ:SEPA) Sees Large Increase in Short Interestmarketbeat.com - April 28 at 6:56 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIceCure MedicalNASDAQ:ICCMIceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.InspireMDNYSE:NSPRInspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. SEP AcquisitionNASDAQ:SEPASEP Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was formerly known as Mercury Ecommerce Acquisition Corp. and changed its name to SEP Acquisition Corp. in December 2022. SEP Acquisition Corp. was incorporated in 2021 and is based in Houston, Texas. SEP Acquisition Corp. operates as a subsidiary of Mercury Sponsor Group I LLC. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.